| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7547776 | SANOFI AVENTIS US | Process for the production of fludarabine-phosphate lithium, sodium, potassium, calcium and magnesium salts and purification process for the production of fludarabine-phosphate and fludarabine-phosphate with a purity of at least 99.5% |
Dec, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7148207 | SANOFI AVENTIS US | Oral fludara of high-purity formulation with quick release of active ingredient |
Dec, 2022
(1 year, 4 months ago) | |
Oforta is owned by Sanofi Aventis Us.
Oforta contains Fludarabine Phosphate.
Oforta has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Oforta are:
- US7148207
- US7547776
Oforta was authorised for market use on 18 December, 2008.
Oforta is available in tablet;oral dosage forms.
Oforta can be used as treatment of patients with b-cell chronic lymphocytic leukemia (cll).
The generics of Oforta are possible to be released after 20 December, 2022.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Dec 18, 2011 |
| Orphan Drug Exclusivity(ODE) | Dec 18, 2015 |
Drugs and Companies using FLUDARABINE PHOSPHATE ingredient
Market Authorisation Date: 18 December, 2008
Treatment: Treatment of patients with b-cell chronic lymphocytic leukemia (cll)
Dosage: TABLET;ORAL
More Information on Dosage
OFORTA family patents
